Anika names Luppino new COO

Anika Therapeutics has named Frank J. Luppino as its chief operating officer.

Gilead Sciences announced that as part of the ongoing integration of CV Therapeutics, Louis G. Lange, MD, PhD has decided to assume a part-time position at Gilead and will therefore be transitioning from his role as Executive Vice President, Cardiovascular Therapeutics.

Abraxis BioScience has appointed Marty Duvall as its new senior vice president of global marketing and international commercial operations.

inVentiv Clinical Solutions has promoted Scott Treiber, PhD, formerly Senior Vice President, Clinical Operations, to Executive Vice President, Clinical Development Solutions.

Premier Research Group Limited has named Hal Ward, R.Ph., PharmD as Executive Director, Global Pharmacovigilance.

Cyntellect appointed Gareth Jones as its European Director of Sales and Operations.

Biotica Technology announced the appointment of Dr. Alan Lewis as a Non-Executive Director.

Transgenomic has appointed Antonius Schuh and Michael McNulty to its board of directors.

Advana Science announced that Mark A. Smith, PhD, a leading researcher in Alzheimer's disease, has been named scientific advisor to the company.

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i